Cancel anytime
Doximity Inc (DOCS)DOCS
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/18/2024: DOCS (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Upturns
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Profit: -43.96% | Upturn Advisory Performance 1 | Avg. Invested days: 27 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 09/18/2024 |
Type: Stock | Today’s Advisory: PASS |
Profit: -43.96% | Avg. Invested days: 27 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 09/18/2024 | Upturn Advisory Performance 1 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.32B USD |
Price to earnings Ratio 50.2 | 1Y Target Price 34.29 |
Dividends yield (FY) - | Basic EPS (TTM) 0.8 |
Volume (30-day avg) 2138022 | Beta 1.27 |
52 Weeks Range 19.71 - 40.99 | Updated Date 09/18/2024 |
Company Size Mid-Cap Stock | Market Capitalization 7.32B USD | Price to earnings Ratio 50.2 | 1Y Target Price 34.29 |
Dividends yield (FY) - | Basic EPS (TTM) 0.8 | Volume (30-day avg) 2138022 | Beta 1.27 |
52 Weeks Range 19.71 - 40.99 | Updated Date 09/18/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 32.53% | Operating Margin (TTM) 36.51% |
Management Effectiveness
Return on Assets (TTM) 10.61% | Return on Equity (TTM) 16.86% |
Revenue by Products
Revenue by Products - Current and Previous Year
Valuation
Trailing PE 50.2 | Forward PE 38.61 |
Enterprise Value 6719672695 | Price to Sales(TTM) 14.83 |
Enterprise Value to Revenue 13.61 | Enterprise Value to EBITDA 33.87 |
Shares Outstanding 125165000 | Shares Floating 120530862 |
Percent Insiders 3.3 | Percent Institutions 93.67 |
Trailing PE 50.2 | Forward PE 38.61 | Enterprise Value 6719672695 | Price to Sales(TTM) 14.83 |
Enterprise Value to Revenue 13.61 | Enterprise Value to EBITDA 33.87 | Shares Outstanding 125165000 | Shares Floating 120530862 |
Percent Insiders 3.3 | Percent Institutions 93.67 |
Analyst Ratings
Rating 3.33 | Target Price 26.3 | Buy 2 |
Strong Buy 4 | Hold 10 | Sell - |
Strong Sell 2 |
Rating 3.33 | Target Price 26.3 | Buy 2 | Strong Buy 4 |
Hold 10 | Sell - | Strong Sell 2 |
AI Summarization
Comprehensive Overview of Doximity Inc.
Company Profile:
History and Background: Doximity Inc. (DOCS) is a leading digital platform for healthcare professionals in the United States. Founded in 2010, the company initially focused on building a professional social networking platform for doctors, similar to LinkedIn. Over time, Doximity has diversified its offerings, expanding into telemedicine, e-prescribing, and other healthcare-related services.
Core Business Areas:
- Social Networking: Doximity's flagship platform connects over 2.2 million verified U.S. healthcare professionals, enabling secure communication, collaboration, and knowledge sharing.
- Telehealth: Doximity Dialer offers HIPAA-compliant video conferencing and secure messaging for virtual consultations.
- E-Prescribing: Doximity's e-prescribing solution streamlines the prescription process for healthcare providers.
- Other Services: Doximity also provides career development resources, educational tools, and a marketplace for medical supplies.
Leadership and Corporate Structure: Doximity is led by CEO and Founder, Dr. Jeff Tangney. The executive team comprises experienced industry veterans with expertise in healthcare, technology, and business development. The company operates under a single-class stock structure, with Dr. Tangney holding a controlling interest.
Top Products and Market Share:
Top Products:
- Doximity Network: The largest online professional network for U.S. healthcare professionals.
- Doximity Dialer: A HIPAA-compliant telehealth platform.
- Doximity ePrescribe: An electronic prescribing solution.
Market Share:
- Social Networking: Doximity holds a dominant market share in the U.S. online professional network for healthcare professionals, with over 80% penetration among physicians.
- Telehealth: Doximity Dialer is gaining traction, but faces competition from established players like Teladoc and Amwell.
- E-Prescribing: Doximity's e-prescribing solution has a growing market share, but competes with larger players like Surescripts and Allscripts.
Product Performance and Competitive Comparison:
- Doximity's Network enjoys high user engagement and positive feedback. Dialer's user base is growing, and ePrescribe is gaining traction through integrations with Electronic Health Records (EHRs).
- Compared to competitors, Doximity's focus on the U.S. healthcare market and its integrated platform provide a competitive advantage. However, larger competitors have established market share and wider adoption in specific segments.
Total Addressable Market:
The global digital health market is estimated to reach $356.8 billion by 2027, with the U.S. market accounting for a significant portion. The market for online professional networks, telehealth solutions, and e-prescribing solutions within this sector represents Doximity's total addressable market.
Financial Performance:
Recent Financial Statements: Doximity's revenue has grown significantly in recent years, driven by strong user growth and expansion into new services. Profitability is also improving, with the company achieving its first profitable quarter in Q2 2023.
Year-over-Year Comparison: Revenue and earnings per share (EPS) have shown consistent year-over-year growth. The company has a strong balance sheet with significant cash reserves.
Cash Flow and Balance Sheet: Doximity generates strong operating cash flow and maintains a healthy balance sheet with low debt levels. This provides the company with the financial flexibility to invest in growth initiatives and pursue acquisitions.
Dividends and Shareholder Returns:
Dividend History: Doximity is currently not paying dividends, as the company prioritizes reinvesting its profits into growth.
Shareholder Returns: Doximity's stock has performed exceptionally well since its IPO in 2021, delivering strong returns for investors.
Growth Trajectory:
Historical Growth: Doximity has experienced rapid user and revenue growth over the past few years. The company has expanded its product offerings and established partnerships with major healthcare organizations.
Future Growth Projections: Analysts expect Doximity's growth to continue, driven by increasing adoption of its platform by healthcare professionals and expansion into new markets and service offerings.
Recent Product Launches and Strategic Initiatives: Doximity continues to launch new features and services, such as Dialer's appointment scheduling capabilities and integrations with EHRs. The company is also pursuing strategic partnerships to expand its reach and deepen its engagement with healthcare professionals.
Market Dynamics:
Industry Trends: The digital health market is undergoing significant growth, driven by factors like the increasing adoption of telehealth, the shift towards value-based care, and the rising prevalence of chronic diseases.
Doximity's Positioning: Doximity is well-positioned to benefit from these trends with its focus on building a comprehensive platform for healthcare professionals. The company's strong brand recognition, user engagement, and strategic partnerships give it a competitive edge.
Adaptability to Market Changes: Doximity has demonstrated its ability to adapt to changing market dynamics, as evidenced by its expansion into new service areas and its focus on data-driven innovation.
Competitors:
Key Competitors:
- Teladoc (TDOC)
- Amwell (AMWL)
- Surescripts (SURI)
- Allscripts (MDRX)
Market Share and Comparison: Doximity leads in the online professional network space for healthcare professionals. In telehealth and e-prescribing, it faces competition from established players with larger market share. However, Doximity's integrated platform and focus on the U.S. market offer differentiation.
Potential Challenges and Opportunities:
Key Challenges:
- Maintaining rapid user growth and engagement.
- Expanding into new markets and services while maintaining profitability.
- Competing with larger established players in the telehealth and e-prescribing markets.
Potential Opportunities:
- Expanding internationally.
- Developing new features and services that cater to the evolving needs of healthcare professionals.
- Leveraging data and analytics to personalize user experiences and improve platform engagement.
Recent Acquisitions (last 3 years):
Doximity has not made any acquisitions in the last 3 years.
AI-Based Fundamental Rating:
Rating: 8.5 out of 10
Justification: Doximity possesses strong fundamentals, supported by its:
- Leading market position in the U.S. healthcare professional network space.
- High user engagement and growth potential.
- Strong financial performance and healthy balance sheet.
- Diversified product offerings and strategic partnerships.
While competition remains a challenge, Doximity's focus on innovation and its unique positioning within the healthcare market provide a strong foundation for future growth.
Sources and Disclaimers:
Sources:
- Doximity Investor Relations website
- SEC filings
- Market research reports
Disclaimer: This information is intended for general knowledge and informational purposes only and does not constitute financial advice. It is essential to conduct your own research and due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Doximity Inc
Exchange | NYSE | Headquaters | San Francisco, CA, United States |
IPO Launch date | 2021-06-24 | Co-Founder, CEO & Chairperson | Mr. Jeffrey A. Tangney |
Sector | Healthcare | Website | https://www.doximity.com |
Industry | Health Information Services | Full time employees | 827 |
Headquaters | San Francisco, CA, United States | ||
Co-Founder, CEO & Chairperson | Mr. Jeffrey A. Tangney | ||
Website | https://www.doximity.com | ||
Website | https://www.doximity.com | ||
Full time employees | 827 |
Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with digital tools built for medicine, that enables its members to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. It primarily serves physicians, nurse practitioners, physician assistants, medical students, pharmaceutical manufacturers, and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.